Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
161.08 USD 1.19 ( 0.74%)
Last update at 2026-11-04T21:02:00Z
VOLUME
3461014
Market Cap
41153.17M
P/E
131.81

Momentum Score

…

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
160.29
Low
170.49
High
52 Week Price Range
238.62
Low
495.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alnylam Pharmaceuticals develops RNA interference therapeutics for genetic and cardio-metabolic diseases, with a clinical-stage pipeline focused largely on liver-targeted indications. Long-term growth may be supported by uptake of approved medicines, progress of late-stage candidates, the GalNAc delivery platform enabling subcutaneous dosing, and international launches.
Key risks include clinical or regulatory setbacks for pipeline programs, competition from alternative modalities and established biopharma players, pricing and reimbursement pressures for orphan and specialty drugs, and operational dependence on a small number of products.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
159.89
Dividend Yield
-
Revenue TTM
3713.94M
Revenue Per Share
28.35
Gross Profit TTM
3032.07M
Debt / Equity
1.62
ROE
73.28%
Net Debt
-378.86M
ROCE
14.33%
Diluted EPS TTM
2.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 323.15M -377.38M -433.52M -1126.99M -852.14M
Net income 313.75M -278.16M -440.24M -1131.16M -852.82M
Selling general administrative 1210.71M 975.53M 795.65M 770.66M 620.64M
Gross profit 3036.77M 1924.87M 1517.89M 868.60M 704.14M
Reconciled depreciation 55.66M 56.67M 97.03M 85.55M 89.69M
Ebit 501.58M -235.52M -312.30M -785.07M -708.65M
Ebitda 557.24M -178.85M -258.24M -894.44M -709.12M
Depreciation and amortization 55.66M 56.67M 54.05M -109.37M -0.47M
Non operating income net other - - - -185.95M -0.47M
Operating income 501.58M -176.88M -282.18M -785.07M -708.65M
Other operating expenses 3212.36M 2425.13M 2110.47M 1822.49M 1552.94M
Interest expense 252.63M 141.86M 121.22M 155.97M 143.02M
Tax provision 9.40M -99.22M 6.72M 4.16M 0.68M
Interest income 111.47M 121.99M 95.56M 24.81M 1.58M
Net interest income -141.16M -19.87M -25.66M -131.16M -141.44M
Income tax expense 9.40M -99.22M 6.72M 4.16M 0.68M
Total revenue 3713.94M 2248.24M 1828.29M 1037.42M 844.29M
Total operating expenses 2535.19M 2101.76M 1800.06M 1653.67M 1412.80M
Cost of revenue 677.17M 323.37M 310.41M 168.82M 140.14M
Total other income expense net -178.43M -200.49M -151.34M -341.92M -143.49M
Net income from continuing ops 313.75M -278.16M -440.24M -1131.16M -852.82M
Net income applicable to common shares - - - -1131.16M -852.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4966.33M 4239.98M 3829.88M 3546.36M 3643.30M
Intangible assets 593.73M - 697.78M 264.56M -
Other current assets 281.89M 116.96M 126.38M 132.92M 111.94M
Total liab 4177.15M 4172.90M 4050.52M 3704.58M 3055.10M
Total stockholder equity 789.18M 67.09M -220.64M -158.22M 588.20M
Other current liab 1300.27M 887.47M 713.01M 585.75M 494.14M
Common stock 1.32M 1.29M 1.26M 1.24M 1.20M
Capital stock 1.32M 1.29M 1.26M 1.24M 1.20M
Retained earnings -6702.52M -7287.75M -7009.59M -6569.35M -5438.19M
Other liab - - - 406.37M 1402.35M
Other assets - 61.83M - 115.48M 101.09M
Cash 1657.25M 966.43M 812.69M 866.39M 819.98M
Total current liabilities 1466.35M 1186.27M 967.79M 767.91M 1191.30M
Current deferred revenue 4.84M 55.48M 102.75M 42.10M 301.84M
Net debt -378.86M 1776.99M 1869.94M 453.85M 177.62M
Short term debt 45.52M 154.90M 96.50M 41.97M 321.89M
Short long term debt total 1278.39M 2743.42M 2682.63M 1320.25M 997.59M
Other stockholder equity 7510.47M 7388.06M 6811.06M 6454.54M 6058.45M
Property plant equipment - - - 523.49M 501.96M
Total current assets 4050.66M 3295.28M 2982.70M 2692.25M 2868.78M
Net tangible assets - - - -158.22M 588.20M
Short term investments 1251.23M 1728.08M 1626.69M 1326.01M 1615.59M
Net receivables 777.57M 405.31M 327.79M 237.96M 198.57M
Long term debt 1007.78M 1024.62M 1020.78M 1016.94M 675.70M
Inventory 82.72M 78.51M 89.15M 128.96M 122.70M
Accounts payable 115.72M 88.42M 55.52M 98.09M 73.43M
Accumulated other comprehensive income -20.10M -34.52M -23.38M -44.65M -33.26M
Common stock total equity - - - 1.24M 1.20M
Retained earnings total equity - - - -6569.35M -5438.19M
Non currrent assets other 81.63M 133.90M -3526.75M 115.48M 40.89M
Non current assets total 915.67M 944.70M 847.18M 854.11M 774.52M
Capital lease obligations 270.61M 271.43M 284.61M 303.31M 321.89M
Long term debt total - - - 1016.94M 675.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 497.18M -116.84M -235.60M 169.35M -192.56M
Change to liabilities - - - 191.77M 88.24M
Total cashflows from investing activities 436.33M -116.84M -336.35M 169.35M -273.30M
Net borrowings -544.53M 0.00M 0.00M 254.00M 500.00M
Total cash from financing activities -305.19M 294.16M 172.13M 425.75M 1247.12M
Change to operating activities - - - -81.68M -72.44M
Net income 313.75M -278.16M -440.24M -1131.16M -852.82M
Change in cash 690.15M 153.77M -53.67M 46.40M 323.11M
Begin period cash flow 968.65M 814.88M 868.56M 822.15M 499.05M
End period cash flow 1658.81M 968.65M 814.88M 868.56M 822.15M
Total cash from operating activities 524.08M -8.31M 104.16M -541.27M -641.69M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 55.66M 56.67M 97.03M 85.55M 89.69M
Other cashflows from investing activities 57.62M 57.76M -4.44M -13.19M -4.36M
Change to inventory 8.47M 13.59M 18.37M -34.14M -26.41M
Change to account receivables -359.96M -86.55M -87.94M -45.60M -101.80M
Sale purchase of stock - - - 259.36M 246.27M
Other cashflows from financing activities -8.27M -8.79M 24.67M 928.50M 1247.12M
Change to netincome - - - 307.71M 223.39M
Capital expenditures 58.70M 34.28M 62.21M 72.06M 76.37M
Change receivables - - - -45.60M -101.80M
Cash flows other operating - - - 125.66M -19.86M
Cash and cash equivalents changes - - - 53.83M 332.12M
Change in working capital -444.78M -214.08M 10.76M -35.55M -162.82M
Stock based compensation 348.24M 272.08M 221.68M 230.65M 165.72M
Other non cash items 253.42M 261.94M 214.93M 309.24M 174.24M
Free cash flow 465.38M -42.59M 41.95M -613.33M -718.07M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALNY
Alnylam Pharmaceuticals Inc		 1.19
0.74%		 161.08 131.81 34.97 11.08 52.15 10.64 62.59
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

675 West Kendall Street, Cambridge, MA, United States, 02142

617 551 8200

https://www.alnylam.com

2500

Name Title Year Born
Mr. Michael W. Bonney B.A. Exec. Chairman 1958
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB CEO & Director 1963
Dr. Akshay K. Vaishnaw M.D., Ph.D. Pres 1963
Mr. Jeffrey V. Poulton M.B.A. CFO & Exec. VP 1968
Mr. Tolga Tanguler M.B.A. Exec. VP & Chief Commercial Officer NA
Dr. Alfred W. Boyle Ph.D. Chief Technical Operations & Quality Officer NA
Dr. Kevin Joseph Fitzgerald Ph.D. Sr. VP, Head of Research & Chief Scientific Officer 1968
Ms. Christine Regan Lindenboom Sr. VP of Investor Relations & Corp. Communications NA
Ms. Indrani M. Lall Franchini J.D. Exec. VP, Chief Legal Officer & Sec. 1972
Mr. Piyush Sharma J.D. Chief Ethics & Compliance Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…